MA46541A - METHODS OF REDUCING PROTEINURIA IN A HUMAN SUBJECT WITH IMMUNOGLOBULIN A NEPHROPATHY - Google Patents
METHODS OF REDUCING PROTEINURIA IN A HUMAN SUBJECT WITH IMMUNOGLOBULIN A NEPHROPATHYInfo
- Publication number
- MA46541A MA46541A MA046541A MA46541A MA46541A MA 46541 A MA46541 A MA 46541A MA 046541 A MA046541 A MA 046541A MA 46541 A MA46541 A MA 46541A MA 46541 A MA46541 A MA 46541A
- Authority
- MA
- Morocco
- Prior art keywords
- nephropathy
- immunoglobulin
- methods
- human subject
- reducing proteinuria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407979P | 2016-10-13 | 2016-10-13 | |
| US15/399,524 US10736960B2 (en) | 2016-01-05 | 2017-01-05 | Methods for inhibiting fibrosis in a subject in need thereof |
| US15/470,647 US20170253667A1 (en) | 2016-01-05 | 2017-03-27 | Methods for inhibiting fibrosis in a subject in need thereof |
| US201762527926P | 2017-06-30 | 2017-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46541A true MA46541A (en) | 2019-08-21 |
Family
ID=61906454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046541A MA46541A (en) | 2016-10-13 | 2017-10-12 | METHODS OF REDUCING PROTEINURIA IN A HUMAN SUBJECT WITH IMMUNOGLOBULIN A NEPHROPATHY |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3525798A4 (en) |
| JP (1) | JP6893554B2 (en) |
| KR (1) | KR102348939B1 (en) |
| CN (2) | CN110177557A (en) |
| AU (1) | AU2017342428B2 (en) |
| BR (1) | BR112019007426A2 (en) |
| CA (2) | CA3039927C (en) |
| CL (2) | CL2019000909A1 (en) |
| GE (1) | GEP20247587B (en) |
| IL (1) | IL265981A (en) |
| JO (1) | JOP20190068A1 (en) |
| MA (1) | MA46541A (en) |
| MX (1) | MX2019004074A (en) |
| PH (1) | PH12019500711A1 (en) |
| SG (1) | SG11201902941UA (en) |
| UA (1) | UA126908C2 (en) |
| WO (1) | WO2018071701A1 (en) |
| ZA (1) | ZA201902933B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419860A (en) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | Glomerular lobular nephropathy modeling method |
| CN115215937B (en) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | Anti-human MASP-2 antibody, preparation method and application thereof |
| CN117016486A (en) * | 2023-07-20 | 2023-11-10 | 澎立生物医药技术(上海)股份有限公司 | Animal model construction method for IgA nephropathy combined membranous nephropathy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE024996T2 (en) * | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Antibodies to masp-2 |
| US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7626730B2 (en) | 2006-03-31 | 2009-12-01 | Eastman Kodak Company | Method of making a multilevel halftone screen |
| BR112012008970A2 (en) * | 2009-10-16 | 2019-12-10 | Omeros Corp | use of a composition and composition |
| US9102721B2 (en) * | 2011-01-21 | 2015-08-11 | Fibrogen, Inc. | Therapeutic method |
| MX355648B (en) | 2011-04-08 | 2018-04-26 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation. |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| HUE049154T2 (en) * | 2011-05-04 | 2020-09-28 | Omeros Corp | Compositions for inhibiting masp-2 dependent complement acitivation |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| DK3057993T3 (en) * | 2013-10-17 | 2020-11-16 | Omeros Corp | Method for Treating Conditions Associated with MASP-2 Dependent Complement |
| SG11201805695SA (en) * | 2016-01-05 | 2018-07-30 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (en) * | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
-
2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/en unknown
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/en active Pending
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/en active Active
- 2017-10-12 UA UAA201904866A patent/UA126908C2/en unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/en active IP Right Grant
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/en active Pending
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/en unknown
- 2017-10-12 MA MA046541A patent/MA46541A/en unknown
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/en active Search and Examination
-
2019
- 2019-04-01 PH PH12019500711A patent/PH12019500711A1/en unknown
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/en unknown
- 2019-04-11 IL IL265981A patent/IL265981A/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201902933B (en) | 2023-05-31 |
| CN110177557A (en) | 2019-08-27 |
| EP3525798A4 (en) | 2020-07-08 |
| JP6893554B2 (en) | 2021-06-23 |
| PH12019500711A1 (en) | 2019-11-18 |
| KR20190063475A (en) | 2019-06-07 |
| BR112019007426A2 (en) | 2019-07-02 |
| JP2019534271A (en) | 2019-11-28 |
| AU2017342428B2 (en) | 2021-02-04 |
| KR102348939B1 (en) | 2022-01-12 |
| MX2019004074A (en) | 2019-06-10 |
| UA126908C2 (en) | 2023-02-22 |
| WO2018071701A1 (en) | 2018-04-19 |
| GEP20247587B (en) | 2024-01-25 |
| EP3525798A1 (en) | 2019-08-21 |
| CA3039927A1 (en) | 2018-04-19 |
| CA3039927C (en) | 2023-10-10 |
| AU2017342428A1 (en) | 2019-05-23 |
| IL265981A (en) | 2019-06-30 |
| SG11201902941UA (en) | 2019-05-30 |
| JOP20190068A1 (en) | 2019-04-01 |
| NZ753260A (en) | 2021-11-26 |
| CA3210384A1 (en) | 2018-04-19 |
| CL2019000909A1 (en) | 2019-06-14 |
| CL2019003485A1 (en) | 2020-04-13 |
| CN116726163A (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258332A (en) | Antibody agents specific for human cd19 and uses thereof | |
| HK1259019A1 (en) | Anti-pd1 antibodies and methods of use | |
| DK3347030T3 (en) | USE OF PASTEURIZED AKKERMANSIA FOR THE TREATMENT OF METABLE DISEASES | |
| MA42924A (en) | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES | |
| KR20180084817A (en) | Anti-SIGLEC-9 antibodies and methods of using the same | |
| DK3221349T3 (en) | Humanized tau antibodies in Alzheimer's disease | |
| ZA201506085B (en) | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies | |
| FR3036037B1 (en) | PERFECTIONAL ENHANCEMENT HARNESS | |
| DK2994160T3 (en) | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLET IMMUNOGLOBULIN G | |
| IL268748A (en) | Humanized model of kidney and liver disorders | |
| BR112015003032A2 (en) | anti-jagged antibodies and methods of use '. | |
| IL261681A (en) | Antigen-binding fusion proteins with modified hsp70 domains | |
| MA45684A (en) | BRAIN SUPPLY PROTEIN | |
| MA46541A (en) | METHODS OF REDUCING PROTEINURIA IN A HUMAN SUBJECT WITH IMMUNOGLOBULIN A NEPHROPATHY | |
| FR3029193B1 (en) | MICRO-STATION OF BIOLOGICAL PURIFICATION | |
| IL288090A (en) | Expression of antigen-binding proteins in the nervous system | |
| FR3016128B1 (en) | HEAD OF DISTRIBUTION AND APPLICATION. | |
| UA36384S (en) | MULTIFUNCTIONAL CHILDREN'S TRANSFORMER BED | |
| IL290368A (en) | Modified human variable domains | |
| IL281932A (en) | Antibodies directed to filamin-a and therapeutic uses thereof | |
| UA39563S (en) | CHILDREN'S SLEDGES | |
| FR3057894B3 (en) | MODEL OF PARASOL OF APPROVAL | |
| UA35770S (en) | CHILDREN'S TRANSFORMER Easel | |
| FR3045774B1 (en) | MULTI-LOOK ADAPTATION FLANGE | |
| IT201700033290A1 (en) | "IMPROVED BED" |